Somewhat Positive Media Coverage Somewhat Unlikely to Impact Arcturus Therapeutics (ARCT) Share Price

News headlines about Arcturus Therapeutics (NASDAQ:ARCT) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arcturus Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.7852020877311 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

ARCT has been the subject of a number of recent research reports. ValuEngine downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, April 27th. WBB Securities raised shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, June 11th. Zacks Investment Research downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, June 6th. Finally, LADENBURG THALM/SH SH raised shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, May 31st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $4.06.

Shares of NASDAQ:ARCT remained flat at $$7.90 during trading on Friday. 2,682 shares of the company were exchanged, compared to its average volume of 14,892. Arcturus Therapeutics has a twelve month low of $4.78 and a twelve month high of $15.19. The company has a market cap of $84.88 million, a P/E ratio of -2.24 and a beta of 1.18.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Featured Story: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply